Crystal form

Abstract

The present invention relates to novel crystalline forms of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride (HCl salt), pharmaceutical compositions thereof, methods for preparing or isolating such crystalline forms and compositions, and methods of using such crystalline forms and compositions in the treatment of various diseases or disorders mediated by motilin receptor activity.

Description

[Technical Field]

[0001] The present invention relates to novel crystalline forms of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride (HCl salt), pharmaceutical compositions thereof, methods for preparing or isolating such crystalline forms and compositions, and methods of using such crystalline forms and compositions in the treatment of various diseases or disorders mediated by motilin receptor activity. [Background technology]

[0002] The compound (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide is disclosed in WO 2010 / 098145 (Patent Document 1) as a motilin receptor agonist, which is useful for treating disease states mediated by motilin receptor activity, particularly motilin receptor agonist activity, such as gastroesophageal reflux disease; functional dyspepsia; irritable bowel syndrome; constipation; pseudo-intestinal obstruction; paralytic ileus after surgery or other procedures; vomiting; gastric stasis or hypomotility caused by various diseases such as diabetes and / or the administration of drugs, or in patients receiving enteral nutrition therapy; Crohn's disease; colitis; cachexia associated with progressive diseases such as cancer and / or its treatment; and other disorders such as incontinence (see Patent Document 1 and Non-Patent Documents 1 to 4).

[0003] The previously known method for preparing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide, as described in Patent Document 1, merely produces a white solid. A general description of pharmaceutically acceptable salts of the present application's (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide is disclosed, and Patent Document 1 discloses and claims the free base of the compound of the present invention. However, no crystalline form or salt of this compound has actually been described or synthesized in the prior art. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] WO2010 / 098145 [Non-patent literature]

[0005] [Non-Patent Document 1] Perdikis G et al., Am J Surg, 1994, 167, 186-192 [Non-patent document 2] Sanger GJ et al., Nat Rev Gastroenterol Hepatol, 2016, 13, 38-48 [Non-patent document 3] Sharma SS et al., Dig Dis Sci, 1995, 40, 2446-2449 [Non-patent document 4] Logo WE et al., Dis Colon Rectum, 1993, 36, 696-708 [Non-Patent Document 5] Byrn SR et al., Solid-State Chemistry of Drugs 2nd ed., pp 3-43 and 461-503, 1999, Indiana, SSCI, Inc. [Non-patent document 6] Lieberman HA et al., Pharmaceutical Dosage Forms: Tablets, Vol. 1, 2nd ed., pp 1-73, 1989, New York, Marcel Dekker, Inc. Summary of the Invention [Problem to be solved by the invention]

[0006] As is well known to those skilled in the art, finding or producing crystals, crystalline forms, or salt forms is a desirable goal in pharmaceutical development from various perspectives, including pharmaceutical formulation and preparation (see Non-Patent Document 5 and Non-Patent Document 6). Despite the many advantages associated with crystalline and salt forms, the development of stable crystalline forms and / or salts is not always feasible.

[0007] Along these lines, considerable efforts have been made to find or prepare crystals or crystalline forms of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide, which was disclosed by RaQualia Pharmaceutical Co., Ltd. in 2010 (WO2010 / 098145). For example, esters such as ethyl acetate (EtOAc), alcohols such as methanol, ethanol, and isopropyl alcohol, nitriles such as acetonitrile (MeCN), ethers such as diethyl ether, diisopropyl ether, tert-butyl methyl ether (MTBE), and cyclopentyl methyl ether (CPME), cyclic ethers such as 2-methyltetrahydrofuran (2-MeTHF) and tetrahydropyran, ketones such as acetone and methyl ethyl ketone (MEK), and halogenated hydrocarbons such as dichloromethane and chloroform have all been used as recrystallization solvents, but all have failed.

[0008] Furthermore, even contract research organizations specializing in crystallization services have tried intensively but have not been able to obtain a crystalline form. For example, mixed solutions such as ethyl acetate, acetonitrile, tetrahydrofuran (THF), diisopropyl ether, CPME, toluene, ethyl acetate / heptane, ethyl acetate / MTBE, toluene / heptane, and ethyl acetate / CPME have all been used as recrystallization solvents, but all have failed.

[0009] Despite these extensive efforts, no pharmaceutically suitable crystalline form of the free base compound has been identified to date, and the free base compound has so far only been available in an amorphous state (hereinafter "free base amorphous").

[0010] Initial attempts by RaQualia Pharmaceuticals Inc. to obtain pharmaceutically suitable crystalline forms involved adding acidic counterions such as hydrochloric acid, tartaric acid, citric acid, malic acid, succinic acid, phosphoric acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, naphthalene-2-sulfonic acid, pamoic acid, and sulfuric acid to various solvent systems as salt screens, but failed to obtain pharmaceutically suitable crystalline salt forms of the compound.

[0011] After extensive and careful research, the inventors of the present invention have finally succeeded in finding the conditions for preparing crystals that can provide the long-awaited pharmaceutically suitable crystalline form of the compound as a hydrochloride salt, i.e., (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A (hereinafter referred to as “hydrochloride crystalline form A”).

[0012] Additionally, a contract research organization with scientific expertise and technology that provides a complete solution for drug discovery, development, and manufacturing failed to identify any polymorphs other than the hydrochloride crystalline Form A in a preliminary polymorph screening. Furthermore, salt screening failed to identify any other crystalline salt forms that are more pharmaceutically suitable than the hydrochloride crystalline Form A. For example, although various counter ions and salt formation conditions were selected, most of the counter ions failed to produce filterable solids as disclosed in the Reference Examples of the present invention.

[0013] Furthermore, the present inventors evaluated the physical properties of the obtained hydrochloride crystals and found another novel hydrochloride crystalline form, i.e., (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B (hereinafter referred to as "hydrochloride crystalline form B").

[0014] Among the obtained crystalline forms, hydrochloride crystalline form A and hydrochloride crystalline form B were found to be less susceptible to deterioration in purity (decomposition) due to temperature and humidity compared to the amorphous free base of the compound, and therefore hydrochloride crystalline form A and hydrochloride crystalline form B were found to have very high storage stability against temperature and humidity. With regard to storage stability against light, hydrochloride crystalline form A was more stable than the amorphous free base.

[0015] Furthermore, as disclosed in the Examples, the present invention provides a method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A (HCl salt crystalline form A). The method includes mixing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide free base in ethyl acetate with hydrochloric acid to obtain a hydrochloride salt solid. The hydrochloride salt solid is dissolved in tetrahydrofuran containing less than 10% by volume of water with heating, to which ethyl acetate is added, optionally with seed crystals, and the mixture is stirred with heating to obtain hydrochloride salt crystalline form A. More preferably, the hydrochloride solid is dissolved in tetrahydrofuran containing 0.1 to 2.5% by volume of water at 60 to 70°C, and ethyl acetate is added thereto, and optionally seed crystals are added, and the mixture is stirred at 60 to 70°C to grow hydrochloride crystalline form A. The precipitate is filtered and dried to obtain hydrochloride crystalline form A. Those skilled in the art have never previously conceived of such crystallization conditions.

[0016] An object of the present invention is to provide a pharmaceutically suitable crystalline form of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride for use in pharmaceutical formulations that can be prepared simply, economically, and reproducibly and has unexpectedly excellent and consistent performance characteristics, such as filterability, ease of handling, facile purity control, stability, and non-hygroscopicity. It is also an object of the present invention to provide a method for preparing such a crystalline form, as well as compositions and uses containing such a crystalline form.

[0017] That is, the present invention provides the following: [1] The peaks in 2-theta are 14.7 and 17.5 ( o ) (where each peak is + / - 0.2( o (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0018] [1-1] Peaks in 2-theta are 14.7, 17.5, and 22.3 ( o ) (where each peak is + / - 0.2( o (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0019] [2] Peaks in 2-theta are 4.0, 7.9, 14.7, 17.5, and 22.3 ( o ) (where each peak is + / - 0.2(o (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0020] [2-1] Peaks in 2-theta are 4.0, 7.9, 13.6, 14.7, 15.7, 16.7, 17.5, 22.3, 25.5, 27.1, and 31.7 ( o ) (where each peak is + / - 0.2( o (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0021] [3] The (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], and [2-1], further characterized by differential scanning calorimetry (DSC) showing an endothermic event at 254°C (wherein this temperature has an error range of + / - 1°C);

[0022] [4] 3327, 2926, 1707, 1668, 1616, and 700 cm -1 (where each peak is within + / - 2 cm -1(R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], and [3], further characterized by an infrared (IR) spectrum (KBr) exhibiting an absorbance band at 100 nm (with error bars of 0.05);

[0023] [4-1] 4047, 3971, 3327, 2926, 2758, 2712, 2621, 2523, 2490, 2401, 2120, 1952, 1898, 1707, 1668, 1616, 1460, 1385, 1358, 1306, 1250, 1223, 1119, 1061, 1051, 990, 953, 912, 745, 700, 631, 561, and 494 cm -1 (where each peak is within + / - 2 cm -1 (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], and [3], further characterized by an infrared (IR) spectrum (KBr) exhibiting an absorbance band at 100 nm (with error bars of 0.05);

[0024] [5] The peaks in 2-theta are 19.8 and 21.6 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0025] [5-1] Peaks in 2-theta are 17.9, 19.8, and 21.6 ( o) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0026] [6] Peaks in 2-theta are 4.0, 7.9, 15.7, 17.9, 19.8, and 21.6 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0027] [6-1] Peaks in 2-theta are 4.0, 7.9, 15.7, 17.9, 19.8, 21.6, 25.5, and 31.7 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05;

[0028] [7] The (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B according to any one of [5], [5-1], [6], and [6-1], further characterized by differential scanning calorimetry (DSC) showing an endothermic event at 258°C (wherein this temperature has an error range of + / - 1°C);

[0029] [8] A pharmaceutical composition comprising the (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form according to any one of [1], [1-1], [2], [2-1], [3], [4], [4-1], [5], [5-1], [6], [6-1], and [7], together with one or more pharmaceutically acceptable carriers or excipients;

[0030] [9] The pharmaceutical composition according to [8], which is in a dosage form for oral administration, parenteral administration, topical administration, rectal administration, vaginal administration, ocular administration, or aural administration;

[0031]

[10] The pharmaceutical composition according to [9], wherein the dosage form is selected from the group consisting of tablets, soft capsules, hard capsules, trozenges, films, ovules, sprays, patches, suspensions, solutions, syrups, elixirs, modified-release formulations, lotions, creams, ointments, gels, drops, foams, wafers, implants, microemulsions, injections, dry powders, and suppositories;

[0032]

[11] A pharmaceutical composition comprising the step of using the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form according to any one of [1], [1-1], [2], [2-1], [3], [4], [4-1], [5], [5-1], [6], [6-1], and [7], together with one or more pharmaceutically acceptable carriers or excipients;

[0033]

[12] The (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form according to any one of [1], [1-1], [2], [2-1], [3], [4], [4-1], [5], [5-1], [6], [6-1], and [7] for use as a pharmaceutical;

[0034]

[13] Use of the (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form according to any one of [1], [1-1], [2], [2-1], [3], [4], [4-1], [5], [5-1], [6], [6-1], and [7], or the pharmaceutical composition according to any one of [8] to

[11] , in the preparation of a medicament for the curative, palliative, or preventive treatment of a pathology mediated by motilin receptor activity;

[0035]

[14] A method for treating a condition mediated by motilin receptor activity, comprising administering to an animal, including a human, in need of such treatment an effective amount of the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form described in any one of [1], [1-1], [2], [2-1], [3], [4], [4-1], [5], [5-1], [6], [6-1], and [7], or the pharmaceutical composition described in any one of [8] to

[11] ;

[0036]

[15] A method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising adding hydrochloric acid in a first organic solvent to a solution of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide in a second organic solvent; Preferably, the first organic solvent is water, ethyl acetate, water / EtOH, dioxane, DMF, ether, acetone, ethanol, methanol, or THF; Preferably, the second organic solvent is water, ethyl acetate, water / EtOH, dioxane, ethanol, methanol, ether, acetone, DMF, THF, or t-butyl methyl ether; More preferably, the first organic solvent is water, ethyl acetate, water / EtOH, dioxane, ethanol, or THF; More preferably, the second organic solvent is ethyl acetate, THF, or t-butyl methyl ether;

[0037]

[16] A method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising exposing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride solid to tetrahydrofuran containing less than 10% by volume of water while heating;

[0038]

[17] A method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising the steps of adding (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride solid to 0.01 to 5% (v / v) aqueous tetrahydrofuran at 50 to 80° C., and adding ethyl acetate at 50 to 80° C.;

[0039]

[18] A method for preparing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising the steps of heating (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride solid in ethyl acetate at a temperature in the range of 50 to 80° C., followed by cooling to room temperature;

[0040] [18-1] A method for preparing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising the steps of heating (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride solid in ethyl acetate at a temperature in the range of 50 to 80° C., and cooling to room temperature; preferably, the temperature range is 60 to 80° C.;

[0041]

[19] A method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising a step of stirring (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B in an organic solvent to convert it to the hydrochloride crystalline form A at room temperature to 100° C.;

[0042]

[20] A method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to

[19] , comprising stirring (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, wherein the organic solvent is ethyl acetate or THF / ethyl acetate containing less than 1% by volume of water;

[0043]

[21] A method for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising adding seed crystals of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride to obtain hydrochloride crystalline form A;

[0044]

[22] A process for preparing (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of [1], [1-1], [2], [2-1], [3], [4], and [4-1], comprising the step of crystallizing the crystalline form from a solvent; preferably, the solvent is water, ethyl acetate, water / EtOH, dioxane, DMF, ether, acetone, ethanol, methanol, or THF; more preferably, the solvent is ethyl acetate. [Effects of the Invention]

[0045] As mentioned above, in various aspects of drug development, including drug formulation and manufacturing, it is an objective to find or prepare crystals or crystalline forms that have unexpectedly superior physicochemical properties. Surprisingly, it has been found that this objective has been achieved by the present invention, which provides (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A. Prior to the present invention, despite extensive efforts by those skilled in the art, no pharmaceutically suitable crystalline form of said compound had previously been identified.

[0046] The crystalline forms of the present invention have significant and unexpected advantages over the white solid disclosed in prior art WO2010 / 098145: Hydrochloride crystalline form A has been found to be more stable than the solid disclosed in prior art WO2010 / 098145.

[0047] Furthermore, it has been found that the hydrochloride salt crystalline form A of the present invention is amenable to large-scale synthesis and has acceptable solid-state properties for the development of solid dosage forms. [Brief explanation of the drawings]

[0048] [Figure 1] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A. [Figure 2] FIG. 2 shows the differential scanning calorimetry (DSC) of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A. [Figure 3]FIG. 3 shows the infrared (IR) spectrum of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A. [Figure 4] FIG. 4 shows the X-ray powder diffraction (XRPD) pattern of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B. [Figure 5] FIG. 5 shows the differential scanning calorimetry (DSC) of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B. [Figure 6] FIG. 6 shows the infrared (IR) spectrum of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B. [Figure 7] Figure 7 shows the photostability of the amorphous solid (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride (hereinafter referred to as "amorphous hydrochloride"). The data (% area) of the degradation products are expressed as a percentage of the initial value of the initial amorphous hydrochloride sample. [Figure 8] Figure 8 shows the photostability of the amorphous solid (free base amorphous) of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide free base. Data (% area) for degradation products are expressed as a percentage of the initial value for an initial sample of amorphous free base. [Figure 9]9 shows the photostability of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A. Data (% area) of degradation products are expressed as a percentage of the initial value of the initial sample of hydrochloride crystalline form A. DETAILED DESCRIPTION OF THE INVENTION

[0049] Thus, the present invention provides a compound having peaks in 2-theta of 4.0, 7.9, 14.7, 17.5, and 22.3 ( o ); more specifically, the peaks in 2-theta are 4.0, 7.9, 13.6, 14.7, 15.7, 16.7, 17.5, 22.3, 25.5, 27.1, and 31.7 ( o ) (where each peak is + / - 0.2( o The present invention provides crystalline (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline Form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-Kα radiation, containing an error bar of 0.05%.

[0050] Accordingly, the present invention provides crystalline (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline Form A as described above, which is further characterized by differential scanning calorimetry (DSC) showing an endothermic event at 254° C. (wherein this temperature has an error margin of + / − 1° C.).

[0051] The hydrochloride salt crystalline form A described above, which has peaks at 3327, 2926, 1707, 1668, 1616, and 700 cm -1;more specifically: 4047, 3971, 3327, 2926, 2758, 2712, 2621, 2523, 2490, 2401, 2120, 1952, 1898, 1707, 1668, 1616, 1460, 1385, 1358, 1306, 1250, 1223, 1119, 1061, 1051, 990, 953, 912, 745, 700, 631, 561, and 494 cm -1 (where each peak is within + / - 2 cm -1 It is further characterized by an infrared (IR) spectrum (KBr) showing an absorbance band at 1000 nm (with error bars of 0.05).

[0052] In a further aspect, the present invention provides (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A of the present invention for use as a medicament.

[0053] A further aspect of the present invention provides the use of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A of the present invention in the manufacture of a medicament for the curative, preventive, or palliative treatment of any disease mediated by motilin receptor activity, in particular 1) gastrointestinal disorders, 2) diseases characterized by motilin receptor expression regions, and 3) diseases involving a lack of motilin secretion.

[0054] The condition may be selected from the group consisting of gastroesophageal reflux disease; functional dyspepsia; irritable bowel syndrome; constipation; intestinal pseudo-obstruction; paralytic ileus after surgery or other procedures; vomiting; gastric stasis or hypomotility caused by various diseases such as diabetes and / or the administration of drugs, or in patients receiving enteral nutrition therapy; Crohn's disease; colitis; cachexia associated with progressive diseases such as cancer and / or its treatment; and other disorders such as incontinence.

[0055] Another aspect of the present invention provides a method for the treatment of any disease mediated by motilin receptor activity, in particular the curative, preventive or palliative treatment of gastroesophageal reflux disease; functional dyspepsia; irritable bowel syndrome; constipation; intestinal pseudo-obstruction; paralytic ileus following surgery or other procedures; vomiting; gastric stasis or hypomotility caused by various diseases such as diabetes and / or the administration of drugs, or in patients receiving enteral nutrition therapy; Crohn's disease; colitis; cachexia associated with progressive diseases such as cancer and / or their treatment; and other disorders such as incontinence, comprising the administration of a therapeutically effective amount of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline Form A and / or hydrochloride crystalline Form B of the present invention to an animal, including a human, in need of such treatment.

[0056] The (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A of the present invention is useful for the general treatment of conditions mediated by motilin receptor activity.

[0057] The (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline Form A and / or Hydrochloride crystalline Form B of the present invention may also be useful for treating a disorder or condition selected from the group consisting of gastroesophageal reflux disease; functional dyspepsia; irritable bowel syndrome; constipation; intestinal pseudo-obstruction; paralytic ileus after surgery or other procedures; vomiting; gastric stasis or hypomotility caused by various diseases such as diabetes and / or administration of drugs, or in patients receiving enteral nutrition therapy; Crohn's disease; colitis; cachexia associated with progressive diseases such as cancer and / or its treatment; and other disorders such as incontinence.

[0058] A synthetic route for the preparation of (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide is described in WO 2010 / 098145 and in the experimental section below.

[0059] (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A can be prepared by crystallization from a solution of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide in an organic solvent, such as ethyl acetate, by adding hydrochloric acid in an ether, such as diethyl ether or MTBE (t-butyl methyl ether).

[0060] Organic solvents that can be used for crystallization of the hydrochloride salt crystalline form include carboxylic acid esters such as ethyl acetate and tetrahydrofuran. Preferred solvents that can be mixed with ethyl acetate include one or more solvents selected from water; alcohols such as methanol, ethanol, and propanol; ethers such as diethyl ether, tert-butyl methyl ether, dioxane, and tetrahydrofuran; hydrocarbons such as hexane, heptane, cyclohexane, dichloromethane, chloroform, benzene, toluene, and xylene; ketones such as acetone and methyl ethyl ketone; amides such as dimethylformamide and dimethylacetamide; and sulfoxides such as dimethyl sulfoxide.

[0061] The (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline Form A and / or hydrochloride crystalline Form B of the present invention can be administered alone or in combination with one or more other drugs (or any combination thereof). Generally, they are administered as a formulation with one or more pharmaceutically acceptable excipients. The term “excipient” is used herein to describe any ingredient other than the compound of the present invention. The choice of excipient will largely depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

[0062] Thus, as a further aspect of the present invention, there is provided a pharmaceutical composition comprising a (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form and one or more suitable excipients, which composition is suitable for the treatment of conditions mediated by motilin receptor activity.

[0063] As used herein, the term "hydrochloride crystalline form" includes hydrochloride crystalline form A and / or hydrochloride crystalline form B.

[0064] The weight purity of the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A of the present invention is not limited, but preferably, an essentially pure crystalline form can be used in specific embodiments of the present invention.

[0065] For the avoidance of doubt, the term "essentially pure," as used herein, means at least 90% by weight purity. More preferably, "essentially pure" means at least 95% by weight purity, and most preferably, at least 98% by weight purity. References herein to "treatment" include references to curative, palliative and prophylactic treatment. As used herein, the article "a" or "an" refers to both the singular and the plural of the object to which it refers, unless otherwise indicated.

[0066] As used herein, the term "animal" includes mammals and non-mammals. Examples of suitable mammals include, but are not limited to, humans, rodents, companion animals, livestock, and primates. Suitable rodents include, but are not limited to, mice, rats, hamsters, gerbils, and guinea pigs. Suitable companion animals include, but are not limited to, cats, dogs, rabbits, and ferrets. Suitable livestock include, but are not limited to, horses, goats, sheep, pigs, cows, llamas, and alpacas. Suitable primates include, but are not limited to, chimpanzees, lemurs, rhesus monkeys, marmosets, spider monkeys, squirrel monkeys, and vervet monkeys. Examples of suitable non-mammals include birds, reptiles, amphibians, and fish. Examples of birds include, but are not limited to, chickens, turkeys, ducks, and geese. A preferred mammal is a human. For non-human animal administration, the term "pharmaceutical" as used herein may be interchanged with "veterinary."

[0067] Pharmaceutical compositions suitable for the delivery of the hydrochloride salt crystalline forms of the present invention, and methods for their preparation, will be readily apparent to those skilled in the art. Such compositions and methods for their preparation can be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995); Polymorphism: In the Pharmaceutical Industry by Rolf Hilfiker (John Wiley & Sons, 2006).

[0068] Oral administration The hydrochloride salt crystalline forms of the present invention can be administered orally, which may involve swallowing, so that the compound enters the gastrointestinal tract, and / or buccal, lingual, or sublingual administration, by which the compound enters the blood stream directly from the mouth.

[0069] Formulations suitable for oral administration include solid, semi-solid, and liquid systems such as tablets; soft or hard capsules containing multi- or nano-particles, liquids, or powders; lozenges (e.g., containing a liquid fill); chews; gels; fast-dispersing dosage forms; films; ovules; sprays; and buccal or mucoadhesive patches.

[0070] Liquid preparations include suspensions, solutions, syrups and elixirs.Such preparations are used as fillers in soft or hard capsules (for example, made of gelatin or hydroxypropylmethylcellulose), and may typically contain carriers such as water, ethanol, polyethylene glycol, propylene glycol, methylcellulose or suitable oils, and one or more emulsifiers and / or suspending agents.Liquid preparations can also be prepared by reconstitution from solids, for example, sachets.

[0071] The hydrochloride salt crystalline forms of the present invention can also be used in fast-dissolving, fast-disintegrating dosage forms, such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 11 (6), 981-986 (2001).

[0072] For tablet dosage forms, depending on the dosage, the drug may comprise 1% to 80% by weight of the dosage form, more typically 5% to 60% by weight of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methylcellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and sodium alginate. Generally, the disintegrant comprises 1% to 25% by weight of the dosage form, preferably 5% to 20% by weight.

[0073] Binders are generally used to give tablet formulations adhesion.Suitable binders include microcrystalline cellulose, gelatin, sugar, polyethylene glycol, natural and synthetic gum, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose.Tablets can also contain diluents such as lactose (monohydrate, spray-dried monohydrate, anhydrous, etc.), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch, and dibasic calcium phosphate dihydrate. Tablets may also optionally contain surfactants, such as sodium lauryl sulfate and polysorbate 80, and glidants, such as silicon dioxide and talc. If present, the surfactants may comprise from 0.2% to 5% by weight of the tablet, and the glidants may comprise from 0.2% to 1% by weight of the tablet.

[0074] Tablets also generally contain a lubricant, such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulfate. Lubricants generally comprise 0.25% to 10% by weight of the tablet, preferably 0.5% to 3%. Other possible ingredients include antioxidants, colorants, flavors, preservatives, and taste-masking agents. Exemplary tablets contain up to about 80% drug, about 10% to about 90% by weight binder, about 0% to about 85% by weight diluent, about 2% to about 10% by weight disintegrant, and about 0.25% to about 10% by weight lubricant.

[0075] Tablet blends can be directly or roller compressed to form tablets. Alternatively, tablet blends or portions of blends can be wet-, dry-, or melt-granulated, melt-congealed, or extruded before tableting. The final formulation can comprise one or more layers and can be coated or uncoated; it can also be encapsulated.

[0076] Tablet formulations are discussed in H. Lieberman and L. Lachman, Pharmaceutical Dosage Forms: Tablets, Vol. 1 (Marcel Dekker, New York, 1989); Larry L. Augsburger and Hoag W. Stephen, Pharmaceutical Dosage Forms: Tablets, Third Edition, Volume 2: Rational Design and Formulation (Informa Healthcare, published June 2008).

[0077] Consumable oral films for human or veterinary use are typically flexible, water-soluble or water-swellable thin film dosage forms, which may be rapidly dissolving or mucoadhesive, and typically comprise a hydrochloride salt crystalline form of the invention, a film-forming polymer, a binder, a solvent, a humectant, a plasticizer, a stabilizer or emulsifier, a viscosity modifier, and a solvent. Some components of the formulation may perform more than one function.

[0078] Formulations of the hydrochloride salt crystalline form of the present invention may be water-soluble or water-insoluble depending on environmental conditions. Water-soluble compounds may typically comprise 1% to 80% by weight of solute, more typically 20% to 50% by weight. Less soluble compounds may comprise a greater proportion of the composition, typically up to 88% by weight of solute. Alternatively, the hydrochloride salt crystalline form of the present invention may be in the form of multiparticulate beads.

[0079] The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range of 0.01 to 99% by weight, more typically in the range of 30 to 80% by weight.

[0080] Other possible ingredients include antioxidants, colorants, flavors and flavor enhancers, preservatives, saliva stimulants, cooling agents, co-solvents (including, for example, oils), emollients, bulking agents, anti-foaming agents, surfactants, and flavoring agents.

[0081] Films of the present invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper.

[0082] This can be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuum processing.

[0083] Solid formulations for oral administration may be formulated to be immediate and / or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.

[0084] Suitable modified release formulations for the purposes of the present invention are described in U.S. Patent No. 6,106,864. Details of other suitable release techniques, such as high-energy dispersions, osmotic particles, and coated particles, can be found in Verma et al., Pharmaceutical Technology Online, 25(2), 1-14, (2001). The use of chewing gum to achieve controlled release is described in WO00 / 35298.

[0085] Parenteral administration The hydrochloride crystalline form of the present invention can also be administered directly into the bloodstream, into muscle, or into internal organs.Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracranial, intramuscular, intrasynovial, and subcutaneous.Suitable devices for parenteral administration include needle (including, for example, microneedle) injectors, needleless injectors, and infusion techniques.

[0086] Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffers (preferably at pH 3-9), although for some applications they may be more suitably formulated as sterile non-aqueous solutions or as a dry form for use with a suitable vehicle such as sterile, pyrogen-free water.

[0087] The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, is readily accomplished using standard pharmaceutical techniques well-known to those skilled in the art.

[0088] Formulations for parenteral administration can be formulated for immediate and / or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release. Thus, the hydrochloride salt crystalline forms of the present invention can be formulated as suspensions or as solid, semisolid, or thixotropic liquids for administration as implanted depots that provide modified release of the active compound. Examples of such formulations include semisolids and suspensions containing drug-coated stents and drug-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres.

[0089] Topical administration The hydrochloride salt crystalline form of the present invention can also be administered topically, dermally (intradermally), or transdermally to the skin or mucosa. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, antiperspirant powders, finishes, foams, films, skin patches, wafers, implants, sponges, fibers, bandages, and microemulsions. Liposomes can also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol, and propylene glycol. Penetration enhancers can also be incorporated (see, e.g., Finnin and Morgan, J Pharm Sci, 88 (10), 955-958 (October 1999)).

[0090] Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free injection (e.g., Powderject™, Bioject™, etc.). Topical administration can also be achieved using a patch, for example, a transdermal iontophoretic patch.

[0091] Formulations for topical administration may be formulated to be immediate and / or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.

[0092] The hydrochloride salt crystalline forms of the present invention can also be administered intranasally or by inhalation, typically in the form of a dry powder from a dry powder inhaler (alone, in a mixture, e.g., with lactose, or as mixed component particles mixed with a phospholipid, e.g., phosphatidylcholine), as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably one using electrohydrodynamics to generate a fine mist) or nebulizer, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, or as nasal drops. For intranasal use, the powder may contain a bioadhesive agent, e.g., chitosan or cyclodextrin.

[0093] The pressurized container, pump, spray, nebulizer, or inhaler contains a solution or suspension of the hydrochloride salt crystalline form of the invention in, for example, ethanol, aqueous ethanol, or a suitable substitute for the active ingredient, a propellant as a solvent, and an optional surfactant, for example, sorbitan trioleate, oleic acid, or oligolactic acid, for dispersing, solubilizing, or extending the release.

[0094] Prior to use in a dry powder or suspension formulation, the drug product is micronized to a size suitable for delivery by inhalation (typically less than 5 microns). This can be achieved by any suitable comminution method, such as vortex jet milling, fluidized bed jet milling, supercritical fluid processing to produce nanoparticles, high pressure homogenization, or spray drying.

[0095] Capsules (e.g., made of gelatin or hydroxypropylmethylcellulose), blisters, and cartridges for use in inhalers or insufflators can be formulated to contain a powder mixture of the compound of the present invention, a suitable powder base such as lactose or starch, and a performance modifier such as L-leucine, mannitol, or magnesium stearate. Lactose can be anhydrous or in the form of a monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.

[0096] Suitable solution formulations for use in electrohydrodynamic nebulizers to generate a fine mist may contain 1 μg to 20 mg of a compound of the invention per actuation, with actuation volumes varying from 1 μL to 100 μL. A typical formulation may contain the hydrochloride salt crystalline form of the invention, propylene glycol, sterile water, ethanol, and sodium chloride. Alternative solvents that may be used in place of propylene glycol include glycerol and polyethylene glycol.

[0097] Suitable flavors, such as methanol and levomethanol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled / intranasal administration.

[0098] Formulations for inhaled / intranasal administration can be formulated for immediate and / or modified release using, for example, PLGA. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.

[0099] For dry powder inhalers and aerosols, the dosage unit is determined by a valve that delivers a metered amount. Units of the invention are typically adjusted to administer a metered dose or "puff" containing 1 μg to 20 mg of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form. The total daily dose is typically in the range of 1 μg to 100 mg, which can be administered in a single dose or, more usually, as divided doses throughout the day.

[0100] Rectal / vaginal administration The hydrochloride salt crystalline form of the present invention can be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, although various alternatives can be used as appropriate.

[0101] Formulations for rectal / vaginal administration may be formulated to be immediate and / or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.

[0102] Ocular / Ear Administration The hydrochloride crystalline form of the present invention can also be administered directly to the eye or ear, typically in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, gels, biodegradable (e.g., absorbent gels, sponges, collagen) and non-biodegradable (e.g., silicone) implants, wafers, lenses, and microparticle or vesicular systems such as niosomes or liposomes. Polymers such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, cellulose-based polymers such as hydroxypropylmethylcellulose, hydroxyethylcellulose, or methylcellulose, or heteropolysaccharide polymers such as gellan gum, together with preservatives such as benzalkonium chloride, can also be incorporated. Such formulations can also be delivered by iontophoresis.

[0103] Formulations for ocular / aural administration may be formulated to be immediate and / or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.

[0104] Other techniques The hydrochloride salt crystalline forms of the present invention may be combined with soluble polymeric substances such as cyclodextrins and suitable derivatives thereof, or polyethylene glycol-containing polymers to improve their solubility, dissolution rate, taste masking, bioavailability and / or stability for use in any of the above modes of administration. For example, drug-cyclodextrin complexes have proven generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes can be used. As an alternative to direct complexation with drugs, cyclodextrins can be used as auxiliary additives, i.e., carriers, diluents, or solubilizers. The most commonly used for these purposes are alpha-, beta-, and gamma-cyclodextrins, examples of which can be found in WO91 / 11172, WO94 / 02518, WO98 / 55148, and Evrard, B. et al., Journal of Controlled Release 96 (3), pp. 403-410, 2004.

[0105] Dosage For treating or preventing conditions mediated by motilin receptor activity, suitable dosage levels of the hydrochloride salt crystalline form of the present invention range from about 0.0001 to 1000 mg of active compound per day, preferably from about 0.001 to 100 mg per day, more preferably from about 0.005 to 50 mg per day, and most preferably from 1 to 50 mg per day. The compound may be administered on a regimen of 1 to 4 times per day. However, dosages outside these limits may be used in some cases.

[0106] These dosages are based on an average human subject having a body weight of about 60 kg to 70 kg. A physician can readily determine dosages for subjects whose body weight is outside this range, e.g., infants and the elderly. For the avoidance of doubt, references herein to "treatment" include references to curative, palliative, and prophylactic treatment.

[0107] The hydrochloride salt crystalline forms of the present invention can also be optionally combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly for the treatment of conditions mediated by motilin receptor activity. For example, the hydrochloride salt crystalline forms of the present invention as described above can be administered simultaneously, sequentially, or separately in combination with one or more agents selected from the following:

[0108] opioid analgesics, such as morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine, or pentazocine;

[0109] nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin, or zomepirac;

[0110] barbiturate sedatives, such as amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, methohexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal, or thiopental;

[0111] sedating benzodiazepines, such as chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam, or triazolam;

[0112] Sedating H1 antagonists, such as diphenhydramine, pyrilamine, promethazine, chlorpheniramine, or chlorcyclizine;

[0113] sedatives, such as glutethimide, meprobamate, methaqualone, or dichloralphenazone;

[0114] Skeletal muscle relaxants, such as baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol, or orphenadrine;

[0115] NMDA receptor antagonists, such as dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 (MorphiDex®: a combination preparation of morphine and dextromethorphan), topiramate, neramexane, or perzinfotel containing NR2B antagonists, such as ifenprodil, traxoprodil, or (-)-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl-3,4-dihydro-2(1H)-quinolinone;

[0116] alpha-adrenergic agonists, such as doxazosin, tamsulosin, clonidine, guanfacine, dexmedetomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline;

[0117] Tricyclic antidepressants, such as desipramine, imipramine, amitriptyline, or nortriptyline;

[0118] anticonvulsants, such as carbamazepine, lamotrigine, topiramate, or valproate;

[0119] Tachykinin (NK) antagonists, specifically NK-3, NK-2, or NK-1 antagonists, such as (αR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]-naphthyridine-6,13-dione (TAK-637), 5-[[(2R,3S)-2-[(1 R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (MK-869), aprepitant, lanepitant, dapitant, or 3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine(2S,3S);

[0120] Muscarinic antagonists, such as oxybutynin, tolterodine, propiverine, trospium chloride, darifenacin, solifenacin, temiverine, and ipratropium;

[0121] COX-2 selective inhibitors, such as celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib;

[0122] Coal tar analgesics, specifically paracetamol;

[0123] neuroleptics, such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, aripiprazole, sonepiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, bifeprunox, asenapine, lurasidone, amisulpride, balaperidone, palindole, eplivanserin, osanetant, rimonabant, meclineltant, Miraxion®, or sarizotan;

[0124] Vanilloid receptor agonists (e.g., resiniferatoxin) or antagonists (e.g., capsazepine);

[0125] Transient receptor potential cation channel subtype (V1, V2, V3, V4, M8, A1) agonists or antagonists;

[0126] β-adrenergic agonists, for example, propranolol;

[0127] Local anesthetics, e.g., mexiletine;

[0128] Corticosteroids, e.g., dexamethasone;

[0129] 5-HT receptor agonists or antagonists, in particular 5-HT1B / 1D agonists, such as eletriptan, sumatriptan, naratriptan, zolmitriptan, or rizatriptan;

[0130] 5-HT2A receptor antagonists, for example, R(+)-α-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907);

[0131] Cholinergic (nicotinic) analgesics, such as ispronicline (TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), or nicotine;

[0132] Tramadol (registered trademark);

[0133] PDEV inhibitors, such as 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil), (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulfonyl)-phenyl]-5-methyl-7 -Propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil), 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyrimidin-1-yl] ... 1-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;

[0134] α-2-δ ligands, such as gabapentin, pregabalin, 3-methylgabapentin, (1α,3α,5α)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)-proline, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1 -aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid, and (3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid;

[0135] ·Cannabinoids;

[0136] · Metabotropic glutamate subtype 1 receptor (mGluR1) antagonists;

[0137] Serotonin reuptake inhibitors, such as sertraline, demethylsertraline (a metabolite of sertraline), fluoxetine, norfluoxetine (a desmethyl metabolite of fluoxetine), fluvoxamine, paroxetine, citalopram, desmethylcitalopram (a metabolite of citalopram), escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, ritoxetine, dapoxetine, nefazodone, cericlamine, and trazodone;

[0138] noradrenaline (norepinephrine) reuptake inhibitors, for example, maprotiline, lofepramine, mirtazapine, oxaprotiline, fezolamine, tomoxetine, mianserin, bupropion, bupropion's metabolite hydroxybupropion, nomifensine, and viloxazine (Vivalan®), and in particular selective noradrenaline reuptake inhibitors such as reboxetine, specifically (S,S)-reboxetine;

[0139] Dual serotonin-norepinephrine reuptake inhibitors, such as venlafaxine, venlafaxine's metabolite O-desmethylvenlafaxine, clomipramine, clomipramine's metabolite desmethylclomipramine, duloxetine, milnacipran, and imipramine;

[0140] Inducible nitric oxide synthase (iNOS) inhibitors, such as S-[2-[(1-Iminoethyl)amino]ethyl]-L-homocysteine, S-[2-[(1-Iminoethyl)amino]ethyl]-4,4-dioxo-L-cysteine, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(1-Iminoethyl)amino]-5-heptenoic acid, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-5-chloro-3-pyridinecarbonitrile; 2-[[(1R,3S)-3-amino-4-hydroxy-1-( 5-thiazolyl)butyl]thio]-4-chlorobenzonitrile, (2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonitrile, N-[4-[2-(3-chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine, or guanidinoethyl disulfide;

[0141] Acetylcholinesterase inhibitors, e.g., donepezil;

[0142] Prostaglandin E2 subtype 4 (EP4) antagonists, such as N-[({2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}amino)-carbonyl]-4-methylbenzenesulfonamide, or 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid;

[0143] Leukotriene B4 antagonists, such as 1-(3-biphenyl-4-ylmethyl-4-hydroxy-chroman-7-yl)-cyclopentanecarboxylic acid (CP-105696), 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy]-valeric acid (ONO-4057), or DPC-11870;

[0144] 5-lipoxygenase inhibitors, such as zileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone (ZD-2138), or 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504);

[0145] Sodium channel blockers, e.g., lidocaine;

[0146] calcium channel blockers, e.g., ziconotide, zonisamide, mibefradil;

[0147] 5-HT3 antagonists, for example, ondansetron; Chemotherapeutic drugs, such as oxaliplatin, 5-fluorouracil, leucovorin, paclitaxel; ·Calcitonin gene-related protein (CGRP) antagonists; Bradykinin (BK1 and BK2) antagonists; · Voltage-gated sodium-gated channel blockers (Nav1.3, Nav1.7, Nav1.8); Voltage-dependent calcium channel blockers (N-type, T-type); ·P2X (ionotropic ATP receptor) antagonists; Acid-sensing ion channel (ASIC1a, ASIC3) antagonists; · Angiotensin AT2 antagonists; · Chemokine CCR2B receptor antagonists; · Cathepsin (B, S, K) inhibitors; Sigma-1 (σ-1) receptor agonists or antagonists;

[0148] and pharmaceutically acceptable salts and solvates thereof.

[0149] Such a combination exerts excellent therapeutic effects, including synergistic effects.

[0150] Combination medications and kits: One embodiment of the present invention is the combined use of the crystalline hydrochloride form of the present invention and a drug for a disease different from that for which the crystalline hydrochloride form of the present invention is used. The "combination" of the present invention can exist as a "fixed combination" or a "kit of parts combination." A "fixed combination" is defined as a combination in which (i) at least one therapeutic agent other than the hydrochloride crystalline form of the present invention; and (ii) the hydrochloride crystalline form is present in a single unit. A "kit of parts combination" is defined as a combination in which (i) at least one therapeutic agent other than the hydrochloride crystalline form of the present invention; and (ii) the hydrochloride crystalline form is present in multiple units. The components of a "kit of parts combination" can be administered simultaneously, sequentially, or separately. The molar ratio of the hydrochloride crystalline form to the therapeutic agent other than the hydrochloride crystalline form of the present invention used in accordance with the present invention is in the range of 1:100 to 100:1, for example, 1:50 to 50:1, or 1:20 to 20:1, or 1:10 to 10:1. The two drugs can be administered separately in the same ratio.

[0151] The present invention extends to combinations comprising (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline forms and one or more therapeutic agents (e.g., those described above) for simultaneous, separate or sequential use in the curative, preventative or palliative treatment of conditions mediated by motilin receptor activity.

[0152] Example The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to these examples. Those skilled in the art can make various modifications within the scope of the technical concept of the present invention. The following examples are for reference only.

[0153] analysis

[0154] X-ray powder diffraction (XRPD) XRPD analysis is performed using a Riraku RINT-TTR or Riraku MiniFlex600 X-ray powder diffractometer using Cu-Kα radiation. Using a variable temperature sample holder attachment, it is also possible to measure samples under high / low temperature conditions. The instrument is equipped with a fine focus X-ray tube. The tube voltage and amperage were set to 50 kV and 300 mA (RINT-TTR) or 40 kV and 15 mA (MiniFlex600). The divergence slit, scattering slit, and receiving slit were set to 0.5, respectively. o , 0.5 o , and 0.15 mm (RINT-TTR), or 1.25 o , 13.0 mm (Open), and 13.0 mm (Open) (MiniFlex600). Diffracted radiation is detected by a NaI scintillation detector (RINT-TTR) or a D / teX Ultra (MiniFlex600). o ) 2-theta up to 4 o / min (RINT-TTR) or 20 o A theta-2theta continuous scan at 1000 Hz / min (MiniFlex600) is used. A silicon standard is analyzed to check the alignment of the machine. Data is collected and analyzed using a Rigaku X-ray system. Samples are placed in an aluminum sample holder that rotates during data acquisition and is aligned for analysis.

[0155] Thermogravimetry / differential thermal analysis (TG / DTA) TG / DTA is performed using a Seiko 6200R system. Samples are placed in aluminum TG / DTA pans. Each sample is heated at a rate of 5°C / min under a nitrogen purge to a final temperature of 300°C. Metallic indium is used as the calibration standard. Values ​​given are rounded and should be considered approximate.

[0156] Differential scanning calorimetry (DSC) Differential scanning calorimetry (DSC) is performed using a Mettler Toledo DSC822. Samples are placed in aluminum DSC pans and the weights are accurately recorded. The pans are covered with lids containing pinholes, and then the lids are tightened. Each sample is heated at a rate of 5°C / min under a nitrogen purge to a final temperature of 280°C. Indium metal is used as the calibration standard. The values ​​given are rounded and should be considered approximate.

[0157] FT-IR spectroscopy Infrared spectra are acquired on a Shimadzu IRPrestage-21 (FT-IR) spectrophotometer equipped with an air-cooled high-energy ceramic light source, a germanium-coated potassium bromide (KBr) plate for the mid-infrared beam splitter, and a highly sensitive pyroelectric infrared detector (DLATGS). Measurements are performed using the diffuse reflectance method with a diffuse reflectance accessory, the DRS-8000. The sample powder is mixed with a small amount of KBr powder on a sample plate with a diameter of 6 mm and a depth of 1.5 mm. Each spectrum is measured over a 4 cm -1 Represents 40 additional scans collected at a spectral resolution of 100 kHz. A background data set was acquired by filling with KBr powder. Wavelength calibration was performed using polystyrene. The values ​​shown are rounded and should be considered approximate.

[0158] Hygroscopicity testing by dynamic vapor sorption analysis (DVS) Moisture sorption tests are performed using a DVS-1 surface measurement system. Samples are placed on a microbalance within the instrument, and weight changes during adsorption are monitored at 25 °C. One program consists of a sorption scan from 0 to 90% relative humidity (RH) in 5% RH increments, with the sample equilibrated for 360 min or until equilibrium is reached at each step.

[0159] nuclear magnetic resonance (NMR) NMR data were measured at 270 MHz (JEOL JNM-LA 270 spectrometer) or 300 MHz (JEOL JNM-LA 300 spectrometer) using deuterated chloroform (99.8% D) or dimethyl sulfoxide (99.9% D) as the solvent unless otherwise indicated, and data are given in parts per million (ppm) relative to tetramethylsilane (TMS) as the internal standard. Conventional abbreviations used include s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad.

[0160] High-performance liquid chromatography (HPLC) measurement HPLC data are obtained on a Waters Alliance 2695 HPLC system equipped with a 2996 PDA detector using the following conditions: Column: XBridge Phenyl (3.5 μm, 4.6 × 150 mm), Eluent: acetonitrile / 0.3% perchloric acid = 35:65 Detection: UV at 215 nm, Flow rate: 1 mL / min, and Column temperature: 40°C. Data processing is performed using Empower 3 software supplied by Waters.

[0161] Room temperature means 15 to 35°C, but is not limited to this as long as the purpose is achieved. The chemical symbols have the usual meanings: M (mole per liter), L (liter), mL (milliliter), g (gram), mg (milligram), mol (mole), and mmol (millimole).

[0162] Throughout this application, the following abbreviations are used with the following meanings: CPME (cyclopentyl methyl ether), EtOAc (ethyl acetate), EtOH (ethanol), MeCN (acetonitrile), MEK (methyl ethyl ketone), MeOH (methanol), 2-MeTHF (2-methyltetrahydrofuran), MTBE (t-butyl methyl ether), THF (tetrahydrofuran), DMF (N,N-dimethylformamide).

[0163] For other tests, the crystalline forms of the present invention can be distinguished by polarized light microscopy (PLM), scanning electron microscopy (SEM), hot stage optical microscopy, electron crystallography, single crystal X-ray diffraction, quantitative analysis, particle size analysis (PSA) (e.g., particle size, particle size distribution (PSD), and particle shape), specific surface area (SSA) analysis, surface energy analysis (e.g., inverse gas chromatography or IGC), dissolution testing, or a combination of these techniques.

[0164] Example 1 [Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide] This compound is synthesized according to the conventional process described in Example 1 of WO2010 / 098145.

[0165] Example 2 [Preparation of Amorphous Solid of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide Hydrochloride (Amorphous HCl Salt)] (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide (50 mg, 97 μmol) obtained according to the method of Example 1 was dissolved in ethyl acetate (0.75 mL) and 4N hydrochloric acid in ethyl acetate (32 μL, 126 μmol) was added. t-Butyl methyl ether (2.0 mL) was added to the mixture, and the precipitated solid was collected by suction to give the hydrochloride salt as a white powder (46 mg, 83 μmol, 85% yield). Another batch (38 mg, 69 μmol) was prepared in the same way, and the combined white powder (84 mg, 152 μmol) was completely dissolved in dichloromethane (5 mL). After evaporating off the solvent, the resulting solid was dried under reduced pressure at room temperature to give an amorphous solid of the hydrochloride salt (73 mg, 132 μmol, recovery rate 87%).

[0166] Example 3 [Preparation of R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A (HCl salt crystalline form A)] Preparation method 1: 4N HCl in ethyl acetate (2.25 mL, 8.9 mmol) was added to (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide (3.83 g, 7.41 mmol) obtained according to the method of Example 1, and the volatiles were removed in vacuo to give (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride as a gum. The gum was dissolved in ethyl acetate (60 mL) with heating, and the mixture was cooled to room temperature to give a colorless suspended solid. The mixture was stirred under nitrogen at 40°C overnight to give a yogurt-like solid. The volatiles were removed in vacuo to give a colorless solid (4.04 g, 7.30 mmol) as a partially crystalline hydrochloride salt. To a solution of hydrochloride partial crystals (186 mg) in 2% aqueous tetrahydrofuran (5 mL) was added ethyl acetate (5 mL), and the above hydrochloride partial crystals were added as seed crystals. The mixture was gently stirred at room temperature for about 5 minutes, and then the mixture was stirred at 60°C overnight. The precipitate was filtered, washed with ethyl acetate, and dried under vacuum at 50°C to obtain a solid (175 mg) as hydrochloride crystalline form A.

[0167] In this specification, the symbols "α", "θ", "δ" and "ν" may be written as "alpha", "theta", "delta" and "new".

[0168] 1H-NMR (CDCl3) delta: 9.81-9.47 (1H, br), 7.55 (1H, dd, J=8.1, 3.6Hz), 7.30-7.14 (5H, m), 7.07-6.85 (3H, m), 4.92-4.83 (1H, m), 4.78-4.69 (1H, m), 4.47-4.26 (1H, m), 3.95-3.82 (1H, m), 3.72-3.57 (1H, m), 3.51-3.41 (1H, m), 3.18-2.55 (7H, m), 2.46-1.58 (10H, m), 1.35 (3H, s), 1.33 (3H, s). MS (ESI) m / z: 517 (M+H) + .

[0169] Crystallinity by XRPD: Hydrochloride crystalline form A (Figure 1). 2-theta values ​​were 4.0, 7.9, 14.7, 17.5, and 22.3 ( o ) major peaks. More specifically, 2-theta 4.0, 7.9, 13.6, 14.7, 15.7, 16.7, 17.5, 22.3, 25.5, 27.1, and 31.7 ( o ). Each peak has a ±0.2( o ) there is an error.

[0170] Melting point (DSC onset): (Figure 2). The endothermic peak shows an onset temperature of 254°C and a peak temperature of 257°C. Each temperature has an error of + / - 1°C.

[0171] IR (KBr): (Figure 3). 3327, 2926, 1707, 1668, 1616, and 700 cm -1 absorption bands at 4047, 3971, 3327, 2926, 2758, 2712, 2621, 2523, 2490, 2401, 2120, 1952, 1898, 1707, 1668, 1616, 1460, 1385, 1358, 1306, 1250, 1223, 1119, 1061, 1051, 990, 953, 912, 745, 700, 631, 561, and 494 cm -1 Absorption bands at each peak. -1 There is an error.

[0172] Elemental analysis, C 31 H 41 Calculated for ClN4O3: C, 67.3; H, 7.5; Cl, ​​6.4; N, 10.1. Found: C, 66.8; H, 7.5; Cl, ​​6.4; N, 10.0.

[0173] Example 4 [Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A (HCl salt crystalline form A)] Preparation method 2: Amorphous solid (40.5 g, 73.1 mmol) of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride (amorphous HCl salt) obtained according to the method of Example 2 was added portionwise to 2% aqueous tetrahydrofuran (102 mL), and then 2% aqueous tetrahydrofuran (204 mL) was added to obtain a clear solution at 60° C. Ethyl acetate (400 mL) was added to the solution, and the resulting mixture was stirred at 60° C. for 5 minutes. Seed crystals (hydrochloride crystalline form A (20 mg) prepared in Preparation Method 1 of Example 3) are added to the mixture, which is then stirred at 50° C. for 1 hour, then at 40° C. for 1 hour, and then at room temperature overnight. The precipitate is filtered, washed with ethyl acetate, and dried in a vacuum oven at 50° C. for 6 hours to give (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A (37.7 g, 68.2 mmol, 93% recovery) as a solid. Therefore, to obtain the hydrochloride salt crystalline form A, which is useful as a pharmaceutically acceptable salt, the procedure described in Example 4 is preferred. This procedure can be carried out not only with the solvents used in the above examples, but also with MTBE, hydrochloric acid solutions in dioxane, water / EtOH, or other solvents. In the XRPD, melting point (DSC start) and IR (KBr) the same signals as those described in Example 3, Preparation 1 are observed.

[0174] Example 5 [Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A (HCl salt crystalline form A)] Large scale (1 kg scale): 1.2 kg of hydrochloride crystalline form A is prepared from (R)-tert-butyl 3-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-ylcarbamoyl)piperidine-1-carboxylate (1.5 kg, 2.5 mol) obtained according to the conventional method described in Example 1 of WO2010 / 098145 by heating in ethyl acetate at 70° C. with concentrated hydrochloric acid (217 mL, 1.04 equivalents).

[0175] Example 6 [Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B (HCl salt crystalline form B)] (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide (9.8 g, 18 mmol), obtained according to the method of Example 1, was heated to 60° C. in THF (250 mL, 25 vol) and deionized water (1 mL), and additional deionized water (3.2 mL) was added portionwise until the solid was completely dissolved. Ethyl acetate (150 mL, 15 vol) was added dropwise at 60° C. over 30 minutes. After the addition of approximately 50 mL of ethyl acetate, a white solid appeared. The mixture was stirred at 60° C. for 17 hours, then cooled to room temperature at a rate of 5° C. every 30 minutes and stirred at 5° C. for 1 hour. The solid is filtered, washed with anhydrous ethyl acetate (2 x 10 mL), and dried in a vacuum oven at 50 °C for 3 hours to give (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B (5.8 g, 10 mmol, 59% recovery) as a solid.

[0176] Crystallinity by XRPD: Hydrochloride crystalline form B (Figure 4). 2-theta values ​​were 4.0, 7.9, 15.7, 17.9, 19.8, and 21.6 ( o ) major peaks. More specifically, 2-theta 4.0, 7.9, 15.7, 17.9, 19.8, 21.6, 25.5, and 31.7 ( o ). Each peak has a ±0.2( o ) there is an error. Melting point (DSC onset): (Figure 5). The endothermic peak shows an onset temperature of 258°C and a peak temperature of 260°C. Each temperature has an error of + / - 1°C.

[0177] IR (KBr): (Figure 6). 3327, 2926, 1707, 1670, 1616, and 700 cm -1absorption bands at 4049, 3971, 3327, 2926, 2758, 2712, 2621, 2523, 2490, 2401, 2120, 1952, 1898, 1707, 1670, 1616, 1458, 1385, 1356, 1306, 1254, 1221, 1117, 1059, 989, 955, 910, 750, 700, 631, 563, 544, 519, and 494 cm -1 Absorption bands at each peak. + / - 2cm -1 There is an error.

[0178] When hydrochloride form A obtained according to the method of Example 3, 4, or 5 contains hydrochloride form B, stirring a suspension of hydrochloride form A and hydrochloride form B in ethyl acetate with a stir bar at room temperature or 60°C for 6 days will result in complete conversion of hydrochloride form B to hydrochloride form A, and only hydrochloride form A will be obtained. No significant conversion of hydrochloride form A to hydrochloride form B was observed in ethyl acetate and / or THF-water-ethyl acetate (1:0.04:3) mixtures at 60°C, and seeding hydrochloride solutions in THF-water with form B at 5, 25, and 60°C did not result in the appearance of form B.

[0179] Example 7 [Moisture absorption test] Hygroscopicity testing was performed using dynamic vapor sorption (DVS) analysis. Table 1 below shows the weight gain percentages of the hydrochloride crystalline form A, the hydrochloride crystalline form B, the hydrochloride amorphous, and the free base amorphous disclosed in prior art WO2010 / 098145. Form A and Form B of the hydrochloride salt absorb less than 3.4% and 8.6% by weight of water, respectively, at 25°C and 90% relative humidity (RH). On the other hand, the amorphous hydrochloride salt and the amorphous free base absorb 20.5% and 17.9% by weight of water, respectively, at 25°C and 90% relative humidity (RH). Therefore, the amorphous hydrochloride salt and the amorphous free base are much more hygroscopic than Form A and Form B of the hydrochloride salt.

[0180] [Table 1]

[0181] Example 8 [Stability test] Solid-state stability tests are performed using Nagano Science's LH-20-11M, LH-21-11M, LTL-200D3CJ-14, or LTX-01 thermo-humidity chambers. Samples are placed in the chambers and exposed to 25°C / 60% RH or 40°C / 75% RH, and / or measured under light irradiation using a D65 lamp or xenon lamp. The crystal form, thermal behavior, purity, and / or weight change of the samples after exposure or irradiation are evaluated using XRPD, TG / DTA or DSC, HPLC, and a microbalance, respectively.

[0182] In solid-state stability studies under accelerated conditions of 40°C / 75% RH, samples taken 26 and 50 days after exposure showed that for the hydrochloride crystalline form A, no other degradation products were observed after 50 days of storage, except for the degradant in the initial sample (day 0). However, for the hydrochloride amorphous and free base amorphous, one product (retention time 9.6 min) and four products (retention times 3.7, 9.6, 13.1, and 21.3 min, respectively) were observed after 50 days of storage, with the survival rates decreasing to 97.0% and 97.2%, respectively. The hydrochloride salt crystalline form A is found to be more stable than the amorphous hydrochloride salt and amorphous free base disclosed in prior art WO2010 / 098145.

[0183] Example 9 [Photostability test] The photostable samples were placed in a Nagano Science LTL-200D3CJ-14. The samples were placed in a chamber and stored at 25°C / 60% RH. They were then irradiated with a D65 lamp at 4000 lux. After 13, 26, and 50 days of storage, the hydrochloride crystalline form A, amorphous hydrochloride, and amorphous free base samples were analyzed by HPLC.

[0184] Figures 7, 8, and 9 show data on degradation products excluding existing products from the initial sample (Day 0), i.e., peaks that clearly appear on the HPLC chart after storing the initial sample under light irradiation. The relative retention time (RRT) indicates the ratio of the retention time (RT) of the target peak to the retention time (RT) of the main peak. If a peak appears at the same RRT for at least two consecutive storage periods of 13, 26, and 50 days, the peak is recognized as a degradant. As shown in FIG. 7, for the amorphous hydrochloride salt, two, five, and five peaks were generated due to decomposition products caused by irradiation with light after storage periods of 13, 26, and 50 days, respectively. As shown in FIG. 8, for the amorphous free base, two, four, and four peaks were generated due to decomposition products caused by irradiation after storage periods of 13, 26, and 50 days, respectively. As shown in Figure 9, hydrochloride crystalline form A does not produce decomposition products upon irradiation with light.

[0185] Example 10 [Solubility test] 5 mg of hydrochloride crystalline Form A was weighed into a vial, and 20 μL of each of buffer solutions (pH 1.06, 2.98, 4.44, 7.34, 7.40, 9.22) and water for injection (WFI) was added to the vial. The mixture was vortexed and allowed to stand for 15 minutes, but no insoluble matter was observed. The mixture remained a clear solution even after standing for 2 days. The hydrochloride salt crystalline form A exhibits good solubility (>250 mg / mL) in all buffer solutions.

[0186] Example 11 [Chiral Analysis] High-performance liquid chromatography (HPLC) measurement HPLC data are obtained on a Waters Alliance 2695 HPLC system equipped with a 2996 PDA detector using the following conditions: Column: DAICEL CHIRALPAK IC (5 μm, 4.6 × 250 mm), Eluent: n-hexane / ethanol / diethylamine = 87 / 13 / 0.1 (v / v / v), Detection: UV at 254 nm, Flow rate: 1 mL / min, and Column temperature: 40°C. Data processing is performed using Empower 3 software supplied by Waters. In the present invention, the hydrochloride crystalline form A and the hydrochloride crystalline form B exhibit favorable stability and exhibit the above-mentioned utility.

[0187] Example 12 [Static Electricity Induction Test] Considering that highly electrostatically conductive substances are generally difficult to handle under pharmaceutical technology conditions, especially under the pharmacological conditions of conventional industrial crude drugs, and that it is not easy to produce drugs with uniform content, the electrostatic conductivity of the crystals tested in this invention shows favorable results that demonstrate the above-mentioned practicality. The test is carried out by conventional methods.

[0188] Example 13 In vitro pharmacological assays Motilin receptor agonist activity is identified by reporter gene assay using cells expressing the motilin receptor and a reporter gene. The dose-response curve of the assay sample is plotted and calculated to determine the agonist activity (EC50). Hydrochloride crystalline form A showed high potency consistent with earlier samples.

[0189] In summary, Form A and Form B are significantly less hygroscopic, and Form A is more resistant to light-induced degradation compared to the amorphous hydrochloride and amorphous free base. Form A has demonstrated storage stability. No significant changes have been observed in the appearance, XRPD, IR (KBr), melting point (DSC onset), or potency of Form A during storage.

[0190] Reference example 1 [General procedure for the preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide salt]: A solution of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide (approximately 25 mg) in EtOH, THF, MTBE, MeCN, MEK, or EtOAc is equilibrated at elevated temperature (50-70 °C) for approximately 5 minutes before the addition of the counterion solution. A counterion solution such as MeCN, EtOH, MEK, THF, DMSO, dioxane, and / or water is added in an amount equivalent to 1.05 molar equivalents of each mixture. The resulting mixture is then slowly cooled to ambient temperature at 20 °C / hour and equilibrated overnight. The precipitate is isolated by vacuum filtration and dried overnight under vacuum at ambient temperature.

[0191] Reference example 1(a) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide benzenesulfonate The salt formation test with benzenesulfonic acid is carried out by the general procedure described above using the compound in MeCN and a solution of benzenesulfonic acid in MeCN. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0192] When a solution of this compound in EtOAc and benzenesulfonic acid in MeCN is used for salt formation with benzenesulfonic acid by the general procedure above, an oil is obtained but no solid.

[0193] Reference example 1(b) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide citrate The salt formation test with citric acid is carried out by the general procedure described above using the compound in MeCN and a solution of citric acid in MeCN. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0194] When a solution of the compound in EtOAc and citric acid in EtOH is used for salt formation with citric acid according to the general procedure above, an oil is obtained but no solid.

[0195] Reference example 1(c) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide L-malate The salt formation test with L-malic acid is carried out by the general procedure described above using the compound in MeCN and a solution of L-malic acid in MeCN. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0196] When a solution of this compound in EtOAc and L-malic acid in EtOH is used for salt formation with L-malic acid according to the general procedure above, an oil is obtained but no solid.

[0197] Reference example 1(d) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide L-tartrate The salt formation test with L-tartaric acid is carried out by the general procedure described above using the compound in MeCN and a solution of L-tartaric acid in EtOH. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0198] Reference example 1(e) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide p-toluenesulfonate The salt formation test with p-toluenesulfonic acid salt is carried out by the general procedure described above using the compound in EtOAc and a solution of p-toluenesulfonic acid in MeCN. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0199] Reference example 1(f) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide naphthalene-2-sulfonate Salt formation with naphthalene-2-sulfonate is tested using the compound in MeCN and a solution of naphthalene-2-sulfonic acid in MeCN according to the general procedure described above. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0200] Reference example 1(g) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide sulfate The salt formation test with sulfuric acid is carried out by the general procedure described above using the compound in MTBE and a solution of sulfuric acid in EtOH. After the addition of the counterion, the mixture is clear. The solution is evaporated to dryness to give an oil, but no solid.

[0201] Reference example 1(h) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide ethanesulfonate The salt formation test with ethanesulfonic acid is carried out by the general procedure described above using the compound in MEK and a solution of ethanesulfonic acid in MEK. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0202] Using EtOH instead of MEK for salt formation with ethanesulfonic acid gives an oil but not a solid.

[0203] Reference example 1(i) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide methanesulfonate (mesylate salt) The salt formation test with methanesulfonic acid is carried out by the general procedure described above using the compound in MeCN and a solution of methanesulfonic acid in MeCN. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0204] On the other hand, when a solution of the compound in MTBE and methanesulfonic acid in MeCN is used to form a salt with methanesulfonic acid according to the general procedure described above, the mixture is clear after the addition of the counterion. After evaporating the solution to dryness, XRPD analysis reveals that a crystalline mesylate salt is obtained.

[0205] However, in a method similar to the hygroscopicity test described in Example 7, the water adsorption amount of the mesylate crystals was 3.7 wt % at 60% RH and 16.9 wt % at 90% RH.

[0206] Using a method similar to that used in Example 11 for chiral analysis, the mesylate crystals show the presence of a 79:21 mixture of R,S- and R,R-isomers. Subsequent analysis of the post-isothermal sample reveals a chiral purity of 93% (93:7 R,S- and R,R-isomers). However, when the R,R-isomer is spiked into both the pre- and post-isothermal stress samples, the retention time does not match that of the R,R-isomer. The cause of this discrepancy is unknown, but possible reasons for the change in retention time include peak splitting, decomposition, or a retention time shift.

[0207] Therefore, the mesylate crystals are not practical as pharmaceutically acceptable salts.

[0208] Reference example 1(j) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hippurate (hippurate salt) The salt formation test with hippuric acid is carried out by the general procedure described above using the compound in MeCN and a solution of hippuric acid in EtOH. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0209] When the compound in MEK and a solution of hippuric acid in MEK are used to form a salt with hippuric acid according to the general procedure described above, the mixture is clear after the addition of the counterion. After evaporating the solution to dryness, XRPD analysis reveals that crystalline hippuric acid salt is obtained.

[0210] However, in the same method as the hygroscopicity test described in Example 7, the amount of water adsorbed by the hippurate crystals was 16.0% by weight at 90% RH, and partial deliquescence was observed. XRPD analysis of the material after the hygroscopicity test reveals an amorphous material. 1 H-NMR analysis shows that the amount of MEK is reduced to 1.6 wt %. The formation of amorphous material after DVS analysis and the concomitant loss of MEK are consistent with hippurate being an MEK solvate.

[0211] Therefore, hippurate crystals are not practical as a pharmaceutically acceptable salt.

[0212] Reference example 1(k) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride (HCl salt) The test for salt formation with hydrochloric acid is carried out according to the general procedure described above using the compound in MeCN and a solution of hydrochloric acid in water / EtOH. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0213] When a solution of the compound in MeCN and hydrochloric acid in dioxane is used to form a salt with hydrochloric acid according to the general procedure described above, the mixture is clear after the addition of the counterion. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0214] Reference example 1(l) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide phosphate The salt formation test with phosphoric acid is carried out by the general procedure described above using the compound in MeCN and a solution of phosphoric acid in EtOH. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0215] When a solution of the compound in EtOAc and phosphoric acid in EtOH is used for salt formation with phosphoric acid according to the general procedure above, an oil is obtained but no solid.

[0216] The oil was then dissolved in MeCN and MTBE was added. The solution was slightly cloudy and a filterable solid was obtained, but it was not possible to isolate a sufficient amount for analysis.

[0217] Reference example 1(m) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide D-gluconate Salt formation with D-gluconic acid is tested using the compound in MTBE and a solution of D-gluconic acid in dioxane / water (volume ratio 4:1) according to the general procedure described above. After the addition of the counterion, the mixture becomes two layers. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0218] Reference example 1(n) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide 1-hydroxy-2-naphthoate The salt formation test with 1-hydroxy-2-naphthoic acid is carried out using the compound in MEK and a solution of 1-hydroxy-2-naphthoic acid in MEK according to the general procedure described above. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0219] Reference example 1(o) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide L-pyroglutamate The salt formation test with L-pyroglutamic acid is carried out by the general procedure described above using the compound in EtOAc and a solution of L-pyroglutamic acid in EtOH. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, XRPD analysis reveals that an amorphous substance is obtained. No salt crystals are obtained.

[0220] Reference example 1(p) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide L-lactate The salt formation test with L-lactic acid is carried out using a solution of the above compound in MeCN and a solution of L-lactic acid in MeCN according to the general procedure described above. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0221] When a solution of the above compound in EtOAc and a solution of L-lactic acid in EtOH are used to form salts with L-lactic acid according to the general procedure described above, the mixture becomes two layers after the addition of the counterion. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0222] Reference example 1(q) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide glutarate The salt formation test with glutaric acid is carried out using MEK solutions of the above compounds and MEK solutions of glutaric acid according to the general procedure described above. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0223] Reference example 1(r) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide pamoate The salt formation test with pamoic acid is carried out by the general procedure described above using the compound in EtOAc and a solution of pamoic acid in DMSO. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0224] Reference example 1(s) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide nicotinate The salt formation test with nicotinic acid is carried out by the general procedure described above using the compound in MEK and a solution of nicotinic acid in DMSO. After adding the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

[0225] Reference example 1(t) Preparation of (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide sebacate The salt formation test with sebacic acid is carried out by the general procedure described above using the compound in THF and a solution of sebacic acid in THF. After the addition of the counterion, the mixture is clear. After evaporating the solution to dryness, an oil is obtained, but no solid is obtained.

Claims

1. The peaks in 2-theta are 14.7, 17.5, and 22.3 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05%.

2. The peaks in 2-theta were 4.0, 7.9, 14.7, 17.5, and 22.3 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05%.

3. 2. The (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A of claim 1, further characterized by differential scanning calorimetry (DSC) showing an endothermic event at 254°C (wherein this temperature has an error margin of + / - 1°C).

4. 3327, 2926, 1707, 1668, 1616, and 700 cm -1 (where each peak is + / - 2 cm -1 2. The (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A of claim 1, further characterized by an infrared (IR) spectrum (KBr) exhibiting an absorbance band at 100 nm (with an error bar of 0.05).

5. The peaks in 2-theta were 17.9, 19.8 and 21.6 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05%.

6. The peaks in 2-theta were 4.0, 7.9, 15.7, 17.9, 19.8, and 21.6 ( o ) (where each peak is + / - 0.2( o (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B, characterized by a powder X-ray diffraction pattern (PXRD) obtained by irradiation with Cu-K alpha (Cu-Kα) radiation, containing an error bar of 0.05%.

7. 6. The (R)—N—((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B of claim 5, further characterized by differential scanning calorimetry (DSC) showing an endothermic event at 258° C. (wherein this temperature has an error margin of + / −1° C.).

8. 8. A pharmaceutical composition comprising the (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form according to any one of claims 1 to 7, together with one or more pharmaceutically acceptable carriers or excipients.

9. 9. The pharmaceutical composition of claim 8, in a dosage form for oral, parenteral, topical, rectal, vaginal, ocular or otic administration.

10. 10. The pharmaceutical composition of claim 9, wherein the dosage form is selected from the group consisting of tablets, soft capsules, hard capsules, trozenges, films, ovules, sprays, patches, suspensions, solutions, syrups, elixirs, modified release formulations, lotions, creams, ointments, gels, drops, foams, wafers, implants, microemulsions, injections, dry powders, and suppositories.

11. 8. A pharmaceutical composition comprising the use of the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form of any one of claims 1 to 7 together with one or more pharmaceutically acceptable carriers or excipients.

12. The (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form according to any one of claims 1 to 7 for use as a medicament.

13. Use of the (R)-N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form of any one of claims 1 to 7 in the preparation of a medicament for the curative, palliative or prophylactic treatment of a pathology mediated by motilin receptor activity.

14. 10. Use of the pharmaceutical composition of claim 8 in the preparation of a medicament for the curative, palliative or prophylactic treatment of a pathology mediated by motilin receptor activity.

15. 5. A process for preparing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of claims 1 to 4, comprising adding hydrochloric acid in a first organic solvent to a solution of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide in a second organic solvent, wherein the first organic solvent is water / ethanol (EtOH) or dioxane, and the second organic solvent is ethyl acetate (EtOAc) or t-butyl methyl ether (MTBE).

16. 5. A process for preparing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of claims 1 to 4, comprising exposing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride solid to heating in tetrahydrofuran containing less than 10% by volume of water.

17. 5. A process for preparing the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of claims 1 to 4, comprising the steps of adding a solid (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride to tetrahydrofuran containing 0.01 to 5% (v / v) water at 50 to 80°C, and then adding ethyl acetate at 50 to 80°C.

18. 5. A process for preparing the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of claims 1 to 4, comprising the steps of heating (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride solid in ethyl acetate at a temperature in the range of 50 to 80°C, and cooling to room temperature.

19. 5. A process for preparing (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of claims 1 to 4, comprising the step of stirring (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form B in an organic solvent, which is ethyl acetate or THF / ethyl acetate containing less than 1% by volume of water, at room temperature to 100° C. to convert the hydrochloride crystalline form A.

20. 5. A process for preparing the (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride crystalline form A according to any one of claims 1 to 4, comprising the step of adding seed crystals of (R)—N-((S)-1-(4-(3,3-dimethyl-2-oxoindolin-1-yl)piperidin-1-yl)-1-oxo-4-phenylbutan-2-yl)piperidine-3-carboxamide hydrochloride to obtain the hydrochloride crystalline form A.

Images